Skip to main content

ParAllele, Merck to Search for SNPs Linked to Cancer Risk, Drug Response

NEW YORK, July 7 (GenomeWeb News) - ParAllele BioScience and Merck plan to co-discover SNPs linked to cancer susceptibility, prognosis, or drug response, the companies said today.

The deal, which is being funded by Merck, ParAllele will use its SNP-genotyping technology to "characterize the genetic changes in tumor samples" identified by the US-based drug maker.


Details of the agreement were not disclosed.


This is at least the second such collaboration for the companies. Almost exactly two years ago, ParAllele said it would use its lab-in-a-tube technology to develop assays, perform multiplexed genotyping, and provide data analysis for Merck.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.